Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT05615753 Recruiting - Breast Cancer Clinical Trials

Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer Survivors

Start date: January 12, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the feasibility of implementing acupuncture intervention in federally qualified health centers oncology clinics for breast cancer survivors.

NCT ID: NCT05615298 Completed - Breast Cancer Clinical Trials

Study to Evaluate Effectiveness of Investigational Device in the Assistance of Detection and Diagnosis of Breast Cancer

Start date: June 15, 2020
Phase:
Study type: Observational

This study aims to evaluate Effectiveness of Investigational Device, Lunit INSIGHT MMG, in the assistance of Detection and Diagnosis of Breast Cancer during Screening Mammography Interpretation.

NCT ID: NCT05613504 Not yet recruiting - Breast Cancer Clinical Trials

Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer.

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

This study intends to further evaluate the efficacy of acupuncture by comparing the intervention effects of different acupuncture treatment regimens on hot flashes in breast cancer ; and to explore the central effect regulation mechanism of acupuncture intervention on hot flashes based on integrated PET/MRI technology.

NCT ID: NCT05613270 Recruiting - Breast Cancer Clinical Trials

Characterizing Breast Cancer With 18F-FES PET/CT

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

18F-fluoroestradiol (FES) is radioactive labeled estradiol, developed for in vivo visualization of estrogen receptor (ER) using positron emission tomography (PET). In this prospective study, 18F-FES PET/CT will be used to evaluate ER activity of metastatic disease and their potential sensitivity to endocrine therapy in ER-positive breast cancer.

NCT ID: NCT05612100 Recruiting - Breast Carcinoma Clinical Trials

Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients

Start date: July 6, 2022
Phase:
Study type: Observational

This study evaluates endocrine therapy-induced alopecia among postmenopausal and premenopausal female patients with breast cancer. Alopecia is one of the most feared side effects of cancer-directed therapy, causing distress in women starting treatment for breast cancer. While alopecia is a well-known side effect of many chemotherapy drugs, it has also been reported by women undergoing endocrine therapy. Despite the frequent reports of alopecia related to endocrine therapy, hair loss is rarely reported as a side effect of endocrine therapy and the exact characterization of alopecia is not well understood. By having postmenopausal and premenopausal breast cancer patients describe their hair loss symptoms experienced while undergoing endocrine therapy, researchers may be able to better characterize the incidence, timing, duration, and severity of alopecia and whether the different types of endocrine therapy cause more or less trouble in this regard.

NCT ID: NCT05610579 Completed - Clinical trials for Lymphedema, Breast Cancer

The 24 Hour Effects of Remedial Exercises With and Without Compression Therapy on Breast Cancer-related Lymphedema

Start date: November 14, 2022
Phase: N/A
Study type: Interventional

The aim of this study to investigate 24 hours of effects of remedial exercises with and without compression therapy on severity of lymphedema and symptoms of the lymphedema The present study is designed as a non-drug clinical trial. The patients will complete two remedial exercise sessions, one without and one with compression in a randomized order separated by a 3-day wash-out period.The main questions it aims to answer are 1. The 24 hour effects of remedial exercises with and without compression therapy on the severity of lymphedema are different in individuals with lymphedema associated with breast cancer surgery. 2. The 24 hour effects of remedial exercises with and without compression therapy on the symptoms of lymphedema are different in individuals with lymphedema associated with breast cancer surgery.

NCT ID: NCT05609903 Completed - Clinical trials for Breast Cancer Metastatic

Atezolizumab With Nab-paclitaxel for Patients With Triple-negative Stage IV Breast Cancer

Anastase
Start date: November 1, 2019
Phase:
Study type: Observational

The study will evaluate the therapeutic efficacy of the association of Atezolizumab plus nabPaclitaxel in a real life context, in order to document any differences both in terms of activity and safety with respect to the knowledge of the association reported in the literature

NCT ID: NCT05609435 Recruiting - Breast Cancer Clinical Trials

Intervention to Improve the Delivery of Follow-up Care for Low-Risk Breast Cancer

Start date: November 16, 2022
Phase: N/A
Study type: Interventional

This study tests a novel intervention designed to optimize needed survivorship care for low-risk breast cancer survivors while reducing burdensome care with limited health benefits. This study examines whether the intervention, titled REASSURE, improves survivors' preparedness for survivorship. Up to 110 participants will be on study for up to 18 months.

NCT ID: NCT05609058 Recruiting - Breast Cancer Clinical Trials

The Influence of Treatment Position (Prone vs. Supine) on Whole Breast Target

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Radiotherapy after breast conserving therapy plays an important role in early stage breast cancer patients. It not only results in a reduction in local and regional recurrence but also decrease the death rate effectively. For adjuvant radiotherapy, supine positioning is the most common approach and has multiple advantages. Due to deformability and softness of the breast, during simulation and treatment in supine position, the breast stretches over the chest wall, especially in patients with large and pendulous glands. Thus the organs at risk (OARs) received dose increased. The radiotherapeutic toxicity are unavoidable. Some present studies show that the prone positioning of patients can improve dose homogeneity and reduce the dose distribution in OARs in patients with large and pendulous glands. Chinese women have relatively small breasts, the advantages of those have not been established. Therefore, investigators compared the parameters between supine and prone positions for whole breast irradiation after conserving surgery.

NCT ID: NCT05608252 Recruiting - Breast Cancer Clinical Trials

VS-6766+Abema+Fulv in Met HR+/HER- BC

Start date: February 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: - VS-6766 - Abemaciclib - Fulvestrant